LTX-315 is under clinical development by Lytix Biopharma and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LTX-315’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LTX-315 (Oncopore) is under development for the treatment of transdermally accessible tumors including malignant melanoma, head and neck squamous cell carcinoma, lymphoma, soft tissue sarcoma basal cell and squamous cell carcinomas. The drug is formulated as injection and administered through intratumoral route. LTX-315 (Oncopore) is a chemically modified cationic cytolytic nonapeptide which is equally active against drug-sensitive and drug-resistant cancer cells. It is derived from the naturally occurring antimicrobial peptide, bovine lactoferricin. It was also under development for carcinoma and liver cancer.
It was under development for the treatment of non-small cell lung cancer, urothelial carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, triple-negative breast cancer, hepatocellular carcinoma, renal cell carcinoma, Merkle cell carcinoma, small cell lung cancer, squamous cell carcinoma of esophagus, esophageal squamous cell carcinoma (ESCC), cervical cancer.
Lytix Biopharma overview
Lytix Biopharma (Lytix) is a biotechnology company that discovers and develops drugs for cancer. It is investigating LTX-315, an oncolytic peptide to treat solid tumors by generating an immune response against a broad antigen repertoire without the need for identification of the antigens. The company is also evaluating LTX-401 program targeting patients with hepatocellular carcinoma, liver metastases and other deep-seated lesions. It utilizes its proprietary in situ vaccination technology to inject molecules into solid tumors and kill cancer cells by activating the patient’s immune system and enable killer T cells to recognize and eliminate cancer cells. Lytix is headquartered in Oslo, Norway.
For a complete picture of LTX-315’s drug-specific PTSR and LoA scores, buy the report here.